Brain Tumor Drugs Global Market Report 2026

Brain tumor drugs are medications used to treat brain tumors. These include chemotherapy, hormone therapies, anticonvulsants, and painkillers. While some prescription drugs are used to manage symptoms during treatment, chemotherapy specifically targets the reduction or destruction of brain tumors.

The primary drugs for brain tumors include temozolomide, carmustine, cisplatin, bevacizumab, gefitinib, and erlotinib. Temozolomide is used to treat certain types of brain cancer, such as glioblastoma multiforme and anaplastic astrocytoma, in patients with newly diagnosed or recurrent tumors. It belongs to a class of medications known as antineoplastics (cancer drugs). Various tumor types-including medulloblastoma, astrocytoma, oligodendroglioma, primitive neuroectodermal tumors (PNET), and others such as glioma, acoustic neuroma, and meningioma-are treated using these drugs, which are employed across hospital pharmacies, clinics, and similar healthcare settings.

Tariffs have posed challenges for the brain tumor drugs market by increasing the cost of imported active pharmaceutical ingredients and specialized formulations. The impact is particularly significant for temozolomide and bevacizumab segments, with hospital pharmacies in regions such as north america and europe facing higher procurement costs. While production costs have risen, some domestic manufacturers are leveraging tariffs to enhance local production and supply chain resilience, potentially leading to greater regional self-sufficiency and innovation in drug formulations.

The brain tumor drugs market research report is one of a series of new reports from The Business Research Company that provides brain tumor drugs market statistics, including brain tumor drugs industry global market size, regional shares, competitors with a brain tumor drugs market share, detailed brain tumor drugs market segments, market trends and opportunities, and any further data you may need to thrive in the brain tumor drugs industry. This brain tumor drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The brain tumor drugs market size has grown strongly in recent years. It will grow from $4.03 billion in 2025 to $4.26 billion in 2026 at a compound annual growth rate (CAGR) of 5.7%. The growth in the historic period can be attributed to increasing prevalence of brain tumors, advancements in chemotherapy drugs, rising awareness about symptom management, development of hormone therapies, introduction of novel anticonvulsants.

The brain tumor drugs market size is expected to see strong growth in the next few years. It will grow to $5.5 billion in 2030 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to growth of precision medicine, integration of ai in drug discovery, expansion of r&d in oncology, increased healthcare expenditure, rising adoption of targeted therapies. Major trends in the forecast period include personalized chemotherapy treatments, growth in hormone therapy applications, advanced pain management drugs, rising use of anticonvulsants in symptom control, expansion of brain tumor drug pipelines.

The rising number of patients undergoing chemotherapy is expected to drive the growth of the brain tumor drugs market in the coming years. Chemotherapy is a treatment that uses potent drugs to target and destroy rapidly dividing cells, including cancer cells. It serves as a primary approach for treating brain tumors, and the availability of effective chemotherapy drugs significantly influences treatment success. The effectiveness of chemotherapy is critical in extending patient survival and improving quality of life, thereby shaping the market's development. For example, in July 2023, the Centers for Disease Control and Prevention, a US-based government agency, reported that over 1 million cancer patients in the United States receive chemotherapy or radiation annually. Consequently, the increasing number of chemotherapy patients is boosting demand for brain tumor drugs.

Key players in the brain tumor drugs market are focusing on technological innovations, such as targeted RAF kinase inhibitors, to meet the growing need for precision oncology therapies that target specific genetic mutations in brain tumors, minimizing systemic toxicity and enhancing patient outcomes. A RAF kinase inhibitor selectively blocks RAF proteins, part of the MAPK signaling pathway, to inhibit tumor cell proliferation, unlike traditional chemotherapies that non-specifically destroy rapidly dividing cells and often cause broader side effects. For instance, in November 2025, Day One Biopharmaceuticals, a US-based biotechnology company, launched OJEMDA (tovorafenib), a novel therapy for pediatric patients with relapsed or refractory low-grade gliomas harboring BRAF fusions or V600 mutations. Tovorafenib is an oral, once-weekly, brain-penetrant inhibitor that precisely targets mutant RAF proteins, providing strong central nervous system exposure and a mechanism tailored to the tumor's molecular driver. Its features include high selectivity, reduced systemic toxicity compared with traditional chemotherapy, and suitability for pediatric patients, marking a significant advancement in genetically guided therapy for childhood brain tumors.

In September 2024, Stryker Corporation, a US-based medical technology company, acquired NICO Corporation for an undisclosed sum. Through this acquisition, Stryker aims to enhance its minimally invasive neurosurgical solutions, particularly for brain tumor removal and intracerebral hemorrhage treatment, improving patient outcomes and expanding its neurotechnology portfolio. NICO Corporation is a US-based medical device company specializing in minimally invasive neurosurgical technologies, particularly for brain tumor removal.

Major companies operating in the brain tumor drugs market are F. Hoffmann-La Roche Ltd, Novartis AG, Amgen Inc., Pfizer Inc., Merck & Co. Inc., CordenPharma, Eisai Co. Ltd., Emcure Pharmaceuticals Limited, Y-mAbs Therapeutics, Roche India, Novartis Oncology, Arlak Biotech, Healthkind Labs Pvt. Ltd., SwisscheM Healthcare Pvt.Ltd, Apikos Pharma, Kolaz Biotech, CStone Pharma, CARsgen Therapeutics, JW Therapeutics, BeiGene, Astellas Pharma Inc, Otsuka Pharmaceutical Co. Ltd, Daiichi Pharmaceutical and Sankyo, AQVIDA GmbH, Baxter International Inc. (UK), AstraZeneca plc, GlaxoSmithKline plc, Veropharm, Biocad, Bristol-Myers Squibb, Celon Pharma, Celgene Corporation, Johnson & Johnson, Eli Lilly and Company, Sandoz AG, Eurofarma Laboratorios S.A., TUTEUR Argentina, The Takeda Pharmaceutical Company Limited, Pierre Fabre Group, Celnova Pharma, Pfizer S.R.L., Teva Pharmaceutical Industries Ltd., BIOPHARMA-MEA, NeoTX, AID Genomics Limited, Julphar, Sanofi, Novo Nordisk A/S, Bayer, Kitov Pharma Limited, CureTech Ltd., Neopharma, Eurolab, Aspen, Adcock Ingram.

North America was the largest region in the brain tumor drugs market in 2025. Middle East is expected to be the fastest-growing region in the global brain tumor drugs market share during the forecast period. The regions covered in the brain tumor drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the brain tumor drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The brain tumor drugs market consists of sales of Afinitor (Everolimus), Afinitor Disperz (Everolimus), Belzutifan, and Bevacizumab. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Brain Tumor Drugs Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses brain tumor drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for brain tumor drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The brain tumor drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Drugs: Temozolomide; Bevacizumab; Other Drugs
• 2) By End User: Hospital Pharmacies; Retail Pharmacies Or Drug Stores; Other End-Users
• 3) By Mechanism of Action: Chemotherapy Agents; Targeted Therapy; Hormone Therapy
• Subsegments:
• 1) By Temozolomide: Oral Formulation; Injectable Formulation
• 2) By Bevacizumab: Monoclonal Antibody Therapy; Combination Therapy With Chemotherapy
• 3) By Other Drugs: Carmustine; Lomustine; Etoposide; Irinotecan; Novantrone (Mitoxantrone)
• Companies Mentioned: F. Hoffmann-La Roche Ltd; Novartis AG; Amgen Inc.; Pfizer Inc.; Merck & Co. Inc.; CordenPharma; Eisai Co. Ltd.; Emcure Pharmaceuticals Limited; Y-mAbs Therapeutics; Roche India; Novartis Oncology; Arlak Biotech; Healthkind Labs Pvt. Ltd.; SwisscheM Healthcare Pvt.Ltd; Apikos Pharma; Kolaz Biotech; CStone Pharma; CARsgen Therapeutics; JW Therapeutics; BeiGene; Astellas Pharma Inc; Otsuka Pharmaceutical Co. Ltd; Daiichi Pharmaceutical and Sankyo; AQVIDA GmbH; Baxter International Inc. (UK); AstraZeneca plc; GlaxoSmithKline plc; Veropharm; Biocad; Bristol-Myers Squibb; Celon Pharma; Celgene Corporation; Johnson & Johnson; Eli Lilly and Company; Sandoz AG; Eurofarma Laboratorios S.A.; TUTEUR Argentina; The Takeda Pharmaceutical Company Limited; Pierre Fabre Group; Celnova Pharma; Pfizer S.R.L.; Teva Pharmaceutical Industries Ltd.; BIOPHARMA-MEA; NeoTX; AID Genomics Limited; Julphar; Sanofi; Novo Nordisk A/S; Bayer; Kitov Pharma Limited; CureTech Ltd.; Neopharma; Eurolab; Aspen; Adcock Ingram.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.